Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2026)

Royalty Pharma has disclosed Accumulated Expenses across 7 years of filings, most recently posting $107.8 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 25.88% year-over-year to $107.8 million; the TTM figure through Jun 2026 stood at $107.8 million (up 25.88% YoY), while the FY2025 annual figure was $110.8 million, up 13.01% from the prior year.
• Accumulated Expenses came in at $107.8 million for Q2 2026 at Royalty Pharma, up from $25.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $110.8 million in Q4 2025 to a low of $12.6 million in Q3 2023.
• Average Accumulated Expenses over 5 years is $47.2 million, with a median of $45.0 million recorded in 2023.
• Year-over-year, Accumulated Expenses jumped 204.98% in 2024 and decreased 24.39% in 2025.
• Over 5 years, Accumulated Expenses stood at $54.2 million in 2022, then declined by 4.58% to $51.7 million in 2023, then soared by 89.74% to $98.1 million in 2024, then climbed by 13.01% to $110.8 million in 2025, then slipped by 2.75% to $107.8 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $107.8 million in Q2 2026, $25.3 million in Q1 2026, and $110.8 million in Q4 2025.